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Introduction: Two factors that have been shown to affect smoking behavior are the cost of 
cigarettes and the dose of nicotine. Behavioral economics posits that the two factors may be 
related through the concept of unit price (unit price = cost/reinforcer magnitude). According to 
this framework, increases in the cost of a reinforcer and decreases in the magnitude of a 
reinforcer are equivalent manipulations. However, this assumption has not been thoroughly 
tested. Method: Across three studies, a rodent self-administration model was used to assess the 
relationship between increases in nicotine cost and decreases in nicotine dose. In Aim 1, each rat 
experienced six unit prices twice: cost was manipulated and dose was held constant across one 
set of combinations, and cost was held constant and nicotine dose was manipulated across the 
other set of combinations. In Aim 2, the same procedure was used as in Aim 1 except that very 
low nicotine doses, hypothesized to below the threshold for maintaining self-administration, 
were used for the dose manipulation. In Aim 3, the hypothesis that consumption should be the 
same at a single unit price regardless of the cost/dose combination used to create it was tested. 
Results: Results show that across the range of unit prices that maintain consumption, behavior is 
more sensitive to nicotine dose than to nicotine cost. However, when above-threshold doses are 
used, increases in nicotine cost maintain consumption across a smaller range of unit prices than 
decreases in dose. When very low nicotine doses are used for dose reduction, animals consumed 
less nicotine than they did for the ratio-escalation manipulation. Finally, nicotine consumption 
was not equivalent across a variety of unit price combinations forming a single unit price. 
INCREASING NICOTINE COST AND DECREASING NICOTINE DOSE ARE NOT 
EQUIVALENT MANIPULATIONS 
Tracy T. Smith, PhD 
University of Pittsburgh, 2015 
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Discussion: Results of the present study are the first to show that increases in the cost of nicotine 
and decreases in the dose of nicotine are not equivalent manipulations, and they raise questions 
about a fundamental assumption within the behavioral economics framework.  
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1.0  INTRODUCTION 
Urgent action is needed to reduce the prevalence of smoking. While the prevalence of 
smoking in the United States (US) has declined over the last five decades, 43.8 million people 
are still smokers (Ingersoll & Cohen, 2005). Cigarette smoking is extremely harmful, causing 
443,000 deaths in the United States each year, and accounting for one in every five deaths 
(USDHHS, 2010), making cigarette smoking the leading cause of preventable death in the US. 
Reducing the prevalence of smoking is among the most important priorities for public health. 
One factor that is known to influence smoking behavior is the cost of cigarettes. Taxation 
is one of the most historically effective tobacco control interventions. Evidence for the 
effectiveness of cigarette taxation comes from both studies examining the impact of tobacco 
taxation across time in the US, and from the variation in the price of cigarettes across different 
regions (Chaloupka, Yurekli, & Fong, 2012). Increasing the price of cigarettes has been shown to 
drive down cigarette consumption, with every 10% increase in the cost of cigarettes causing an 
estimated 4% decline in cigarette consumption (Chaloupka & Warner, 1999; Jha & Chaloupka, 
1999). When the price of cigarettes is increased, some of the decrease in cigarette consumption is 
because the prevalence of smoking decreased (Chaloupka et al., 2012), meaning that a proportion 
of smokers quit smoking when price is increased. The impact of cigarette taxation has been 
shown to be increased in low socioeconomic status (SES) groups (Townsend, Roderick, & 
Cooper, 1994), and in young people . It is hypothesized that cigarette taxation decreases the 
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proportion of adolescents that transition from experimentation to regular smoking (Chaloupka et 
al., 2012). Some of the impact of taxation on cigarette consumption is offset by substitution. That 
is, smokers will switch to another tobacco product if prices are not raised uniformly across 
products (Laxminarayan & Deolalikar, 2004). However, noncombustible products often carry 
reduced health risks compared to combustible cigarettes, so the shift to noncombustible products 
may be desirable in comparison to use of traditional cigarettes. 
Another factor that has recently been shown to impact smoking behavior is nicotine 
content. A reduction in the nicotine content within cigarettes has received attention as a potential 
strategy for reducing the harm caused by tobacco. In 2009, the FDA was given the authority to 
regulate cigarette constituents, including nicotine to any non-zero level. Existing nicotine 
research is promising, with data suggesting there is no increase in toxicant exposure, there is no 
compensatory smoking at very low nicotine contents past the first few cigarettes, and in some 
cases there is a decrease in cigarettes per day after a few weeks of use (Benowitz et al., 2012; 
Benowitz et al., 2007; Donny, Houtsmuller, & Stitzer, 2007; Hatsukami, Kotlyar, et al., 2010; 
Hatsukami, Perkins, et al., 2010). 
One framework, behavioral economics, suggests that the two factors, nicotine cost and 
nicotine content, may function to change behavior in the same way (Smith, Sved, Hatsukami, & 
Donny, 2014). Behavioral economics is a subfield of psychology that uses concepts from 
microeconomics to characterize changes in behavior. According to this framework, changes in 
the consumption of a reinforcer occur as a function of the unit price of that reinforcer, and unit 
price combines both the cost and the magnitude (i.e., drug dose) of the reinforcer (unit price = 
reinforcer cost / reinforcer magnitude).  From this perspective, increasing the cost of nicotine and 
decreases in the magnitude of each nicotine reinforcer should result in an equivalent change in 
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unit price, and should result in the same change in consumption. For example, if the price per 
pack of cigarettes were doubled, that increase in unit price should result in the same change in 
cigarette consumption as if the number of cigarettes in a pack were reduced by half with the cost 
remaining constant. Thus, if nicotine is the primary reinforcing component of a cigarette, 
decreasing the content of nicotine may be functionally equivalent to raising the cost of nicotine 
(or raising the cost of cigarettes) (Smith et al., 2014).  
A fundamental concept in the field of behavioral economics is the demand curve. An 
example is plotted in Figure 1 using data from a single subject in a recently completed study 
(Smith et al., In Press). A demand curve plots the consumption of a reinforcer as a function of 
the unit price of that reinforcer (Hursh & Roma, 2013; Hursh & Silberberg, 2008).  
 
 
 
 
Figure 1. Example demand curve for an individual subject. 
 
 
From this perspective, the individual cost and reinforcer magnitude components making up a 
given unit price are irrelevant, with the critical variable being the ratio between the two 
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components. Demand curves can be used to characterize how behavior changes as a function of 
unit price. Research shows that demand curves for reinforcers generally follow a uniform pattern 
(Hursh & Silberberg, 2008): demand curves have a negative slope such that consumption of a 
reinforcer decreases as unit price of that reinforcer increases. Across a range of low unit prices, 
demand is inelastic, meaning that the decrease in consumption is proportionally less than the 
increase in unit price (i.e., the slope of the demand curve is shallower than -1). Over this range of 
doses, responding for the reinforcer increases with increases in unit price. At some unit price 
(termed Pmax), demand becomes elastic, meaning that the decrease in consumption is 
proportionally more than the increase in unit price (i.e., the slope of the demand curve is steeper 
than -1). Over this range of prices, responding for the reinforcer decreases with increases in unit 
price (Hursh & Roma, 2013).  
Demand curves have been shown to conform well to an exponential equation (Hursh & 
Silberberg, 2008) (shown in Figure 1; Equation 1) in which Q is consumption at a given unit 
price, C, and k is a scaling parameter. Q0 and α are the two free parameters, with Q0 being the 
predicted consumption if the reinforcer were free (graphically the y-intercept), and α is the rate at 
which consumption changes as a function of unit price (graphically the rate of change in the 
slope). α has been described as a measure of the essential value of a reinforcer. After the 
exponential equation has been fit to obtained consumption data, the equation can be used to 
predict consumption at any unit price.  
Behavioral economics has been used for a variety of purposes. One of its primary uses is 
to characterize changes in self-administration behavior of drugs of abuse (Hursh, 1991). The 
sensitivity of an organism to changes in unit price might be thought of as a measure of the 
essential value of the reinforcer, and behavioral economics allows for the estimation of this value 
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in a single parameter (α) that describes the change in the demand function as unit price is 
increased (Hursh & Silberberg, 2008). Sensitivity to unit price might be thought of as a measure 
of drug abuse liability (Hursh, 1991). Demand curves can also be used to characterize changes in 
consumption of other reinforcers as the unit price of the first reinforcer is manipulated (Hursh & 
Roma, 2013). For example, behavioral economics could characterize changes in alcohol 
consumption as the cost of cigarettes is escalated. Researchers have recently suggested that 
demand curves could be used to describe how agonist and antagonist drug therapies change drug-
taking behavior (Hursh & Roma, 2013). Other recent uses for behavioral economics include how 
changes in income might change cigarette smoking behavior (Koffarnus, Wilson, & Bickel, 
2014), predicting compulsive drug-taking behavior in a rodent self-administration model 
(Bentzley, Jhou, & Aston-Jones, 2014), describing the role of the serotonin transporter gene in 
alcohol-taking behavior (Lamb & Daws, 2013), and characterizing how subpopulations of 
individuals differ in drug-taking behavior (i.e., individuals with schizophrenia) (MacKillop & 
Tidey, 2011).  
Behavioral economics has been occasionally used to characterize changes in tobacco or 
nicotine use. For example, it has been used to characterize changes in cigarette smoking as a 
function of increases in the cost of cigarettes by manipulating the monetary cost of cigarettes 
(Acker & Mackillop, 2013; Grace, Kivell, & Laugesen, 2014; MacKillop et al., 2012; MacKillop 
et al., 2008), and the effort required to obtain cigarette puffs (Shahan, Bickel, Badger, & 
Giordano, 2001; Shahan, Bickel, Madden, & Badger, 1999). There is one instance in which 
behavioral economics was used characterize changes in nicotine consumption as a function of 
changes in nicotine yield. DeGrandpre, Bickel, Hughes, and Higgins (1992) reanalyzed data 
from 17 studies in which nicotine yield was manipulated either through brand switching (14 
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studies), shortening cigarettes (two studies) or ventilated filters (one study). Estimated nicotine 
consumption was plotted as a function of unit price, and in each case appeared to fit an 
exponential function. This analysis suggests that behavioral economics can be useful for 
characterizing changes in behavior as a function of changes in nicotine yield. However, in all of 
the studies reanalyzed by DeGrandpre et al. (1992), manipulations of nicotine yield are likely 
accompanied by manipulations of other non-nicotine constituents which may influence the value 
of cigarette reinforcers (Bardo, Green, Crooks, & Dwoskin, 1999; Clemens, Caille, Stinus, & 
Cador, 2009; Smith et al., In Press). To date, no research has used a behavioral economics 
analysis to examine changes in nicotine consumption when the nicotine content within cigarettes 
is directly manipulated.  
Behavioral economics has also been mostly neglected as a tool in rodent nicotine self-
administration studies, with a couple of recent exceptions. In one paper, a behavioral economics 
analysis was applied post-hoc to a data set in which the number of responses required to earn a 
nicotine infusion was increased across sessions (Diergaarde, van Mourik, Pattij, Schoffelmeer, & 
De Vries, 2012), showing that a measure of impulsivity was related to elasticity of demand for 
nicotine. Another recently completely study from our lab (Smith et al., In Press) used behavioral 
economics to characterize how other cigarette constituents might shift sensitivity to cost of 
nicotine. Only two studies have used behavioral economics to examine changes in rodent self-
administration behavior by manipulating the concentration of nicotine (Grebenstein, Burroughs, 
Roiko, Pentel, & LeSage, 2015; Grebenstein, Burroughs, Zhang, & LeSage, 2013), and nicotine 
consumption conformed well to Equation 1 (Hursh & Silberberg, 2008), suggesting behavioral 
economics may be a useful future measure in other nicotine self-administration studies where the 
concentration of nicotine is manipulated. 
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An important assumption embedded in the behavioral economics approach is that a 
reduction in the dose of nicotine is functionally equivalent to an increase in cost. If this 
assumption holds true, then increases in the price of cigarettes would be functionally equivalent 
to decreases in the nicotine content in cigarettes, because they are both manipulations of unit 
price (Smith et al., 2014). In this case, existing literature examining how escalating cost changes 
cigarette consumption could be leveraged to better understand the likely outcomes of nicotine 
reduction. For example, changes in cigarette consumption as a function of taxation are inelastic, 
meaning that the decrease in cigarette consumption is proportionally less than the increase in 
price (Chaloupka et al., 2012). These data suggest that at the current price of cigarettes, changes 
in nicotine consumption as a function of small changes in nicotine content are also likely to be 
inelastic, meaning that decreases in nicotine content will result in increases in smoking behavior. 
Thus, a large decrease in nicotine content may be required to decrease smoking behavior. We 
also know that about half of the impact of cigarette price on cigarette consumption is a result of 
changes in the prevalence of smoking (Chaloupka et al., 2012), which suggests that if nicotine 
content is decreased a proportion of adults may quit smoking. Finally, if the two manipulations 
are equivalent, then the impact of a nicotine reduction policy is likely dependent on the cost of 
cigarettes. Cigarette cost varies widely across the US, and across countries, so it may be 
appropriate to think of a target unit price for nicotine reduction instead of a target nicotine 
content (Smith et al., 2014). The price of a pack of Marlboro cigarettes in Norway is $15.11 
(USD), but is as low as $0.74 in the Philippines. If cost is an equal determinant of smoking 
behavior following implementation of a nicotine reduction policy, then the threshold nicotine 
dose required for maintaining smoking behavior would be approximately 20 times less in the 
Philippines than in Norway (World Lung Foundation & American Cancer Society, 2012).  
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If increases in cigarette cost and decreases in nicotine content are equivalent 
manipulations, we can use research on cigarette taxation to make predictions about individual 
differences in response to nicotine reduction. For example, cigarette taxation has been shown to 
be more effective in young people and individuals of low SES (Chaloupka et al., 2012; 
Townsend et al., 1994), so these individuals may be especially sensitive to decreases in nicotine 
content. Furthermore, demand parameters derived from hypothetical increases in the cost of 
cigarettes (i.e., Cigarette Purchase Task) have been shown to be related to clinical outcomes such 
as nicotine dependence and treatment motivation (Chase, Mackillop, & Hogarth, 2013; 
MacKillop et al., 2008; MacKillop & Tidey, 2011; Murphy, MacKillop, Tidey, Brazil, & Colby, 
2011)). These data suggest that lower dependence and increased motivation to quit smoking may 
be predictive of better nicotine reduction outcomes. Furthermore, an individual’s sensitivity to 
increases in monetary cost of cigarettes may predict an individual’s sensitivity to decreases in 
nicotine content. Sensitivity to increases in cost may be characterized efficiently using 
hypothetical tasks like the Cigarette Purchase Task, in which individuals predict how many 
cigarettes they would smoke if cigarettes were a variety of prices. This task might also be useful 
for characterizing the sensitivity of vulnerable subpopulations to cost. This information could 
then be used to predict how those subpopulations would respond to decreases in nicotine dose.  
The equivalence of reinforcer cost and reinforcer magnitude relies on the assumption that 
the critical factor in determining the level of reinforcer consumption is the cost per unit of a 
reinforcer, but the two manipulations will produce markedly different patterns of reinforcer 
delivery that may impact the level of reinforcer consumption. When cost is increased, the same 
bolus of drug is delivered with each reinforcer delivery, but when dose is decreased, smaller 
infusions of drug are delivered and many reinforcer deliveries are required to earn equivalent 
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consumption. Thus, even if the same level of reinforcer consumption is obtained following the 
two manipulations, the reinforcer will be delivered in infrequent boluses for the cost 
manipulation and in smaller, more frequent boluses for the dose manipulation. Previous research 
suggests that the duration over which a drug is delivered is a critical variable in determining 
whether or not that drug is reinforcing, and in determining the level of drug self-administration 
(Balster & Schuster, 1973; Comer et al., 2009; Panlilio et al., 1998; Schindler, Panlilio, & 
Thorndike, 2009; Sorge & Clarke, 2009; Wakabayashi, Weiss, Pickup, & Robinson, 2010; 
Wakasa, Takada, & Yanagita, 1995; Wing & Shoaib, 2013). Thus, increases in cost and 
decreases in dose may not function to change behavior in the same way because they 
differentially change the pattern of reinforcer delivery. In addition to the difference in the 
delivery pattern of the reinforcer, there will be differences in the pattern of cue delivery. 
Reinforcers are delivered in a complex environment of other stimuli, and some of these stimuli 
may act as conditioned reinforcers through their pairing with other reinforcers (Pavlov, 1927). 
When reinforcer cost is increased, the unit price of those conditioned reinforcers is also 
increased, but when reinforcer magnitude is decreased, the unit price of conditioned reinforcers 
remains the same because the magnitude of the conditioned reinforcers has not been explicitly 
manipulated. If the value of a conditioned reinforcer is proportional to the value of the primary 
reinforcer is has been paired with, over time the value of these conditioned reinforcers should 
decrease because the magnitude of the primary reinforcer has decreased, but the timeline for this 
change is unknown.  
There is quite a bit of existing research investigating the relationship between cost and 
reinforcer magnitude using a behavioral economics analysis. A variety of reinforcers have been 
used to investigate equivalence including food (Collier, Johnson, Hill, & Kaufman, 1986; 
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DeGrandpre, Bickel, Hughes, Layng, & Badger, 1993; Foster & Hackenberg, 2004; Hursh, 
Raslear, Shurtleff, Bauman, & Simmons, 1988; Sumpter, Temple, & Foster, 2004), heroin 
(English, Rowlett, & Woolverton, 1995), morphine (DeGrandpre et al., 1993), 
dextropropoxyphene (English et al., 1995), codeine (DeGrandpre et al., 1993), and pentazocine 
(English et al., 1995), pentobarbital (Bickel, DeGrandpre, Higgins, & Hughes, 1990; 
DeGrandpre et al., 1993), procaine (DeGrandpre et al., 1993), d-Amphetamine (Bickel et al., 
1990; DeGrandpre et al., 1993), ethanol (Bickel et al., 1990), phencyclidine (Bickel et al., 1990; 
Carroll, Carmona, & May, 1991), ketamine (Bickel et al., 1990), methohexital (Bickel et al., 
1990; DeGrandpre et al., 1993), and cocaine (Bickel et al., 1990; DeGrandpre et al., 1993; 
Nader, Hedeker, & Woolverton, 1993; Woolverton & English, 1997). These studies have 
employed one of two techniques for assessing equivalence: 1) plotting consumption at a single 
unit price regardless of the cost / reinforcer magnitude combination used to create that unit price 
and using visual inspection to assess equivalence, or 2) plotting consumption at a variety of unit 
prices on a single demand curve regardless of the cost / reinforcer magnitude combination used 
and using visual inspection to confirm that all data points fall on a single demand curve. These 
techniques are not the most rigorous test of equivalence because they do not directly compare 
manipulations of cost and dose, and they do not require consumption data to meet any standard 
of equivalence. The single most thorough investigation thus far reanalyzed data from 10 drug 
self-administration studies in which at least two FR requirements and two drug doses were 
tested. Data were re-plotted as drug consumption as a function of unit price, and visual 
inspection was used to confirm that all combinations fell on a single demand curve (Bickel et al., 
1990). The data appeared to roughly fit an exponential function. However, this analysis did not 
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employ any statistical techniques to assess equivalence, only one subject was used from each 
previous study, and cost and dose were not directly compared.  
One study has evaluated the relationship between cost and dose using cigarettes (Bickel, 
DeGrandpre, Hughes, & Higgins, 1991). In this study, five participants were given the 
opportunity to perform an effortful response (plunger pulls) to earn puffs of a cigarette. Across 
different sessions, the number responses required to earn cigarette puffs (fixed-ratio, FR) and the 
number of cigarette puffs that could be earned was manipulated.  Two FR/puff combinations 
were created for each of six unit prices. Visual inspection of individual data suggested that 
consumption was generally equivalent between the two combinations of any unit price. 
However, there are several limitations associated with this study. Only five participants were 
tested, visual inspection of consumption data was the primary method of analysis, the 
manipulation of nicotine yield likely also manipulated non-nicotine cigarette constituents and 
cue magnitude, and for one of the five participants nicotine consumption was markedly different 
between the two FR/puff combinations for two of the unit prices.  
Thus far, all research investigating the relationship between increasing cost and 
decreasing drug dose has used drug doses in the range expected to maintain behavior, although 
researchers have hypothesized that this relationship between drug dose and drug cost may 
change when doses outside of the range for maintaining behavior are used (DeGrandpre et al., 
1993; Hursh & Winger, 1995).  If increases in drug cost and decreases in drug dose are not 
equivalent manipulations when doses in the range that maintain behavior are used, it would be 
unlikely that they would be equivalent manipulations when very low drug doses are used. 
However, even if they are equivalent manipulations when drug doses in the range that maintains 
behavior are used, this relationship may be altered at very low doses because low doses may not 
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have any reinforcing value above vehicle administration. If very low doses do not have any 
reinforcing value, consumption may not be maintained even though a unit price approach would 
predict that it would. However, it is possible that at lost costs, multiple deliveries of a very low 
drug dose could be earned with very little time in between and equivalent consumption may be 
maintained.  
It is particularly important to extend the equivalence of reinforcer cost and reinforcer 
magnitude to very low doses for nicotine because a nicotine reduction policy is likely to use very 
low nicotine contents that are hypothesized to be below the threshold for maintaining smoking 
behavior (Sofuoglu & Lesage, 2012). Previous nicotine research suggests that nicotine doses at 
or below 3.75 µg/kg/infusion produce nicotine consumption similar to saline substitution in self-
administration paradigms (Smith et al., 2013). However, the determination of this threshold 
nicotine dose may be dependent on methodological factors. In Smith et al. (2013)’s study, five 
responses were required to earn each infusion, and a behavioral economics framework would 
suggest a lower cost, or number of required responses, would lower the threshold dose for 
maintaining behavior. Additionally, in standard self-administration procedures, each infusion is 
followed by a time out. These time outs prevent the animal from earning multiple infusions in a 
short time span, and necessarily lengthen the time over which rats can earn a larger amount of 
drug. Because the duration of drug delivery has been shown to be a critical variable in 
determining drug consumption (Wing & Shoaib, 2013), time outs may function to decrease drug 
consumption. Additionally, when dose is reduced, subjects must increase the number of 
infusions earned to maintain nicotine consumption. An increase in earned infusions will increase 
time out presentations, and will reduce time available in a session to earn infusions. Thus, typical 
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experimental procedures make it difficult to assess whether increases in cost are equivalent to 
decreases in dose even at very low nicotine doses. 
1.1 TRANSLATIONAL ISSUES ASSOCIATED WITH RODENT NICOTINE SELF-
ADMINISTRATION 
A self-administration paradigm, in which rats receive intravenous infusions of nicotine 
contingent on their own responding, is ideal for assessing the relationship between increasing the 
cost of nicotine and decreasing the dose of nicotine because dose and cost can be tightly 
controlled, and both consumption and responding for nicotine can be precisely measured. In the 
self-administration paradigm, cost is manipulated using the number of responses that are 
required to earn an infusion of nicotine (i.e., fixed-ratios or FRs). Self-administration also 
removes variation in other variables that might contribute to differences in sensitivity to cost for 
humans (e.g., income, exposure to marketing, social pressure and constraints). However, there 
are some difficulties associated with translating this research directly to human smokers. First, a 
behavioral economics approach assumes that each additional response is associated with the 
same marginal increase in effort and time for the organism. However, it may be that the 
relationship between response requirement and cost is not linear, and this may vary depending on 
the typography of the response. For rats in a self-administration paradigm, each additional 
response may be associated with the same marginal increase in cost. However, for human 
smokers, each additional cigarette smoked may only be linearly related to cost within a range, 
and at some threshold level, there may be greater costs associated with additional smoking (i.e., 
work places offering a set number of smoking breaks, respiratory limitations). The rodent self-
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administration model standardizes cost, but results will need to be interpreted with the 
translational limitations in mind.  
Second, in a self-administration paradigm, rats can only change their behavior by altering 
the number of responses they make or the rate at which they make them. However, human 
smokers have more flexibility in how their behavior changes. When unit price is increased, 
smokers may change the number of cigarettes per day that they smoke or they may change the 
way in which they smoke cigarettes (e.g., changes in puff volume, puff duration, inter-puff 
interval, breathe hold time). Thus, human smokers have more flexibility in the pattern of nicotine 
delivery than rats in the self-administration procedure. For example, for rats in the self-
administration procedure, an increase in cost likely means that the time between reinforcer 
deliveries will increase because more time is required to make the increased number of 
responses. However, for human smokers, the pattern of nicotine delivery does not necessarily 
change when the price of cigarettes is increased.  
Third, human smokers take their nicotine in the context of many other variables including 
initially neutral cues that are paired with nicotine over time and cigarette constituents that may 
reinforce behavior on their own or interact with the reinforcing potential of nicotine (Caggiula et 
al., 2009). The rodent self-administration paradigm models environmental variables using an 
initially neutral stimulus that is paired with nicotine. However, non-nicotine cigarette 
constituents may interact with the reinforcing value of nicotine differently in different nicotine 
dose ranges. For example, constituents that inhibit MAO may selectively increase the value of 
low nicotine doses. The neutral cue employed in rodent models is unlikely to model this kind of 
change in value across the nicotine dose-response curve. Because of these differences between 
human smoking and rodent self-administration procedures, even if the relationship between 
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increasing cost and decreasing dose is strong in the present experiments, additional barriers may 
be present when translating this concept to the human smoker.  
1.2 THE PRESENT EXPERIMENTS 
The present studies aim to evaluate the relationship between increasing the cost of 
nicotine and decreasing nicotine dose. Aim 1 evaluated how changes in cost of nicotine and 
nicotine dose relate to consumption of nicotine using doses within the range expected to maintain 
self-administration behavior. Aim 2 evaluated whether the relationship between increasing cost 
and decreasing dose is maintained at low doses expected to be below the threshold for 
maintaining behavior. Aim 3 evaluated whether consumption is the same for a single unit price 
when combinations are used that employ nicotine doses both above and below the hypothesized 
threshold for self-administration. 
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2.0  AIM 1 
2.1 PURPOSE 
The purpose of Aim 1 was to evaluate whether increases in nicotine cost and decreases in 
nicotine dose change behavior in the same way when the doses used are above the hypothesized 
threshold for reinforcing behavior. Previous research from our lab suggests that the threshold for 
nicotine self-administration is between 7.5 µg/kg/infusion and 3.75 µg/kg/infusion (Smith et al., 
2013). Thus, the lowest dose used in the present experiment was 7.5 µg/kg/infusion.  
2.2 METHODS 
2.2.1 Subjects 
Male Sprague-Dawley rats (Harlan-Farms, IN) weighing between 200 and 225 g on the 
day after arrival were used as subjects (n=44). Data are pooled from two cohorts of rats that 
completed the experimental procedures at separate times. Rats were housed individually in tub 
cages on a ventilated rack with an automatic watering system. Temperature in the colony room 
was kept between 68 and 70 degrees Fahrenheit. Rats were kept on a reverse light-dark 12:12 
hour schedule, and testing occurred during the dark phase. Rats received ad libitum chow for the 
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first seven days while habituating to individual home cages. At least eight days after arrival, rats 
were implanted with jugular catheters and were changed to a feeding schedule where 20 g/day 
was delivered after each session. Rats were allowed at least five days of recovery following 
surgery.  
2.2.2 Apparatus 
Thirty-eight standard self-administration operant chambers (ENV-008 CT; Med-
Associates) were configured as previously described (Smith et al., 2013), and included two nose 
poke holes below two stimulus lights on one side of the chamber. 
2.2.3 Drugs 
 Nicotine hydrogen tartrate salt (Sigma, St. Louis, MO) was dissolved in 0.9% saline 
(doses expressed as free base). All solutions were sterilized by being passed through a 0.22 μm 
filter. Nicotine was delivered in a volume of 0.1 ml / kg in approximately 1 s. 
2.2.4 Procedures 
2.2.4.1 Surgery 
Procedures for jugular catheterization were as previously described (Smith et al., 2013). 
For the first five days following surgery, the first cohort of rats had their cannulae flushed once 
daily with a sterile saline solution containing heparin (3 U), timentin (6.67 mg) and streptokinase 
(833.3 U) to maintain catheter patency and prevent infection. After this initial post-surgery time 
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period, the flushing solution contained only the heparin and timentin. The second cohort of rats 
had the same flushing procedures except that timentin was unavailable after the surgical recovery 
period, and 10mg cefazolin was substituted. Only data points from rats that passed a patency test 
consisting of rapid loss of muscle tone to methohexital (5 mg/kg i.v.) are included.  
2.2.4.2 General Self-Administration Procedures 
Rats were given the opportunity to respond via nosepokes for i.v. infusions. The side of 
the active nosepoke hole (left vs. right) was counterbalanced across rats. Active pokes resulted in 
a simultaneous onset of an intravenous infusion, a 3-s cue light presentation and time-out period 
according to the reinforcement schedule in effect. Active nosepokes during time out and inactive 
nosepokes were recorded, but had no consequence. Sessions lasted at least two hours and were 
conducted seven days per week.  
Time-out and session length 
This set of experiments employed a novel time out procedure. In traditional procedures, 
the session time is fixed, and each infusion produces a time out from reinforcement (lab standard 
is 1-min). This creates an inequity between increasing cost and decreasing dose because when 
unit price is increased, the number of infusions is likely to increase only for the dose reduction, 
reducing the time available in the session to respond. In the present study, a novel procedure was 
employed such that the time out period was 3 s, and each time out extended the length of the 
session by 3 s. This procedure ensures that each rat had two hours of time-in to respond, 
regardless of the number of infusions earned. A shorter time out than traditionally used was 
employed to allow rats receiving low nicotine doses at low costs to earn nicotine infusions with a 
short inter-infusion interval.   
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2.2.4.3 Acquisition 
Rats started self-administration of 60 µg/kg/infusion on an FR2 schedule of self-
administration, and reached a training condition of 60 µg/kg/infusion on an FR10 schedule of 
reinforcement before beginning the unit price manipulation. The two cohorts of rats reached the 
training condition differently. The first cohort of rats responded for 60 µg/kg/infusion nicotine 
on an FR2 schedule of reinforcement. After 13 days, self-administration behavior was stable, and 
the unit price portion of the experiment began. After two unit price combinations, self-
administration behavior was very low, likely as a result of large changes in FR requirement, 
which functioned as extinction when rats never made enough responses to experience the 
contingency. The “training condition” was then established. Rats were given four sessions on 
this training procedure before continuing on through the unit price procedure, and experienced a 
single training condition session in between each unit price combination. At the end of the 
experiment, the first two unit price combinations were repeated, and only data from those 
repetitions is included here.  
The second cohort of rats experienced an increase in FR across sessions to reach the 
terminal FR used in the training condition (FR10) before beginning the unit price manipulation. 
Rats experienced 11 sessions on FR2, 7 sessions on FR5, and 10 sessions on FR10. Rats then 
began the unit price portion of the experiment described below.  
2.2.4.4 Unit Price Procedure 
Rats each experienced six unit prices, and each rat experienced each unit price twice, 
creating 12 total combinations (Table 1). The first six combinations all used the same dose of 
nicotine, but the number of responses required to earn an infusion (FR, cost) increased across 
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unit prices. The second six combinations all required the same number of responses to earn an 
infusion, but the dose of nicotine decreased across unit prices. Nicotine doses in this experiment 
were chosen to be in a range that is expected to maintain self-administration behavior (Smith et 
al., 2013). Rats experienced four sessions at each unit price combination, and each rat 
experienced the combinations in a random order. Rats experienced one session on the training 
condition (FR10, 60 µg/kg/infusion) in between each unit price combination.  
Table 1. FR/Dose combinations used in Aim 1 
2.2.4.5 Data Analysis  
Analyses focused on comparing: 1) consumption for the two combinations at each unit 
price, 2) how the two manipulations change consumption across the range of unit prices that 
maintain consumption, and 3) how the two manipulations change consumption as consumption 
changes from being maintained to not being maintained. To test for significant differences, 
paired samples t-tests were used. Because of the theoretical importance of hypothesized 
equivalence, when no significant differences were found for consumption or for free parameters, 
two one-sided tests of equivalence were used, with the margin of equivalence (δ) set at 25% of 
the overall mean. When comparing breakpoints (ordinal data), a Wilcoxon Signed Ranked Test 
was used. Type 1 error rate (α) was set at 0.05. 
For the second objective, evaluating behavior changes across the range of unit prices that 
maintain consumption, a demand curve analysis was employed. The last two sessions at each 
unit-price combination were used to calculate consumption. Consumption is the total nicotine 
 UNIT PRICE: FR/NICOTINE DOSE (µG/KG/INFUSION) 
 0.133 0.267 0.4 0.533 0.8 1.33 
 FR DOSE FR DOSE FR DOSE FR DOSE FR DOSE FR DOSE 
COST 
ESCALATION 
8 60 16 60 24 60 32 60 48 60 80 60 
DOSE 
REDUCTION 
10 75 10 37.5 10 25 10 18.75 10 12.5 10 7.5 
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infused (in μg/kg). Two demand curves were created for each subject: one for the dose-reduction 
and one for the ratio-escalation, and Equation 1 was fit to each demand curve using a GraphPad 
Prism template provided by the Institute for Behavior Resources at no cost 
(http://www.ibrinc.org/index.php?id=181). For each rat and each demand curve, data points were 
excluded if consumption fell below 10% of baseline (average consumption over final two 
training condition sessions prior to unit price manipulation) or fell to 0.  
For the third objective, breakpoint (highest unit price maintaining consumption at or 
above 10% of baseline) was compared between the two manipulations. Visual inspection of 
individual demand curves suggested that when breakpoint is reached for ratio-escalation curves, 
the subsequent change in consumption is often drastic, while the change in consumption for 
dose-reduction curves is more gradual. However, the change in consumption immediately 
following breakpoint could not be compared because rats often maintained behavior across the 
full range of dose-reduction combinations tested. Thus, the maximum instance of elasticity was 
compared between the two manipulations. For each data point, the proportional change in 
consumption given the proportional change in unit price was calculated (proportional decrease = 
1 – (% decrease in consumption / % increase in unit price), and the lowest value was compared 
between the two manipulations. Negative values indicate a larger percentage change in 
consumption than the percentage change in unit price.  
2.3 RESULTS 
Of the 44 rats that were used in the experiment, 8 failed the first patency test, and no data 
are included from these rats. Four rats never earned an infusion on the unit price procedure, and 
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their data are excluded (three in the first cohort were removed from the study after the first four 
unit prices, the fourth was in the second cohort and completed the study, but data has been 
excluded). The remaining 32 have usable data for at least some of the unit prices.  
2.3.1 Comparing consumption at each unit price 
Figures 2, 3, 4 show the average and individual consumption data for Aim 1. Figure 2 
shows the average data expressed as a group demand curve (error bars represent standard error).  
 
 
Figure 2. Average consumption for ratio-escalation and dose-reduction unit price combinations. 
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Figures 3 and 4 show the average and individual data shown for each unit price in a bar graph. In 
Figure 3 the data are plotted on a common y-axis to emphasize the decrease in consumption 
across unit prices. In Figure 4, the same data are shown, but each y-axes has been adjusted to 
reveal any differences in consumption between combinations. Consumption appears qualitatively 
similar across the lowest and highest unit prices (e.g., 0.133, 0.267, 1.33), but not at intermediate 
prices.  Six paired samples t-tests conducted using consumption at each of the six unit prices 
were unable to reveal any differences between the two approaches (ps > 0.05). The difference in 
consumption was significantly less than 25% of the overall mean for the two lowest unit prices: 
0.133 and 0.267, but not for any other unit prices (0.133: δ = 184.7, t (26) = 2.208, p < 0.05; 
0.267: δ = 148.5, t (25) = 3.345, p < 0.05; 0.4: δ = 115.1; 0.533: δ: 84.5; 0.8: δ = 56.4; 1.33: δ = 
26.6). Thus, while a paired-samples t-test was unable to reveal that consumption was different 
between the two combinations, most also do not meet a reasonable criterion of equivalence.  
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Figure 3. Average and individual consumption data for all 12 unit price combinations with all y-axes on the same 
scale. 
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2.3.2 Comparing increases in cost and decreases in dose when consumption is maintained 
A demand curve analysis was employed to assess whether manipulations of cost and dose 
change consumption similarly across the range of unit prices that maintain consumption. Only 
data points where consumption was maintained were included (defined as consumption at or 
above 10% of baseline) (Figure 5).  
 
 
 
Figure 4. Average and individual consumption data for all 12 unit price combinations with y-axes adjusted 
for each graph. 
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Four rats had two or less data points on at least one of the two curves, and were not included in 
the demand analysis (n=28 for demand analysis). A large proportion of data points were 
excluded from ratio-escalation curves because consumption was not maintained at high unit 
prices, suggesting that breakpoints likely differ between the two manipulations. An average 
demand curve including only data points where consumption was maintained is shown in Figure 
6 (error bars represent standard error). While average consumption is qualitatively similarly for 
the two lowest unit prices tested, consumption appears more sensitive to changes in dose across 
the remaining four unit prices tested. 
 
Figure 5. Proportion of data points excluded from demand curve 
analysis. 
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Figure 7 shows R
2
 values for the demand curve analysis. Fits were good for both ratio 
and dose fits, but fits were significantly better for dose curves than for ratio curves (t (27) = 
2.777, p < 0.05).  
  
Figure 6. Average consumption for ratio-escalation and dose-reduction unit price 
combinations including only data points that were included in demand analysis. 
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Figure 8 shows free parameters from the best fitting functions of Equation 1 for both Q0 and α. 
Values more than three standard deviations from the mean were excluded (Q0: 2 values, α: 1 
value). Ratio and dose Q0 values were not significantly different from each other (p > 0.05), and 
the difference between the two sets of scores was significantly less than 165 µg, approximately 
25% of the mean (t (25) = 2.074, p < 0.05). This difference is less than three infusions for ratio 
combinations (180 µg/kg). Dose α scores were significantly greater than ratio α scores (t (26) = 
3.411, p < 0.05), suggesting that consumption is more sensitive to dose manipulations across the 
range of unit prices that maintain behavior. Q0 scores were also highly correlated, but the  
Figure 7. R
2
 values for the best fitting functions 
of Equation 1 for 28 rats included in demand 
analysis. 
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correlation of α scores did not meet significance (Figure 9), suggesting that sensitivity to the cost 
of nicotine is a poor predictor of sensitivity to nicotine dose. 
 
 
 
 
 
Figure 8. Free parameters Q0 (a) and α (b) from best fitting functions of Equation 1. 
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2.3.3 Comparing increases in cost and decreases in dose when consumption is not 
maintained 
Breakpoint (BP) was defined as the highest unit price at which consumption was 
maintained at or above 10% of baseline (average of last two training condition sessions prior to 
start of the unit price manipulation) (Figure 10). This analysis was only conducted for rats that 
completed the entire procedure (n=26). A Wilcoxon Signed Ranked Test confirmed that BP was 
significantly higher for the dose procedure than for the ratio procedure (Z = 3.619, p < 0.05). 
Sixteen rats had a higher dose BP than a ratio BP, 10 rats had the same BP for both procedures, 
and 0 rats had a higher ratio BP than a dose BP.  
 
 
 
Figure 9. Correlation between free parameters Q0 (a) and α (b). 
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Visual inspection of individual demand curves suggested that the ratio escalation curves 
tended to decrease drastically after reaching a BP, while dose reduction curves showed a more 
gradual change across unit prices. Three exemplars are shown in Figure 11 (data points falling 
below graph had a value of 0).  
  
Figure 10. Breakpoint unit prices for each of the 26 rats that completed all 12 unit 
prices. 
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It was not possible to compare the change immediately following breakpoint for all rats, 
because for most rats, consumption was maintained across all dose-reduction unit price 
combinations tested. Instead, change in consumption between each unit price was expressed as 
the proportional decrease in consumption given the proportional change in unit price, and the 
largest decrease for each rat for each of the two procedures was selected (Figure 12). This 
analysis might be thought of as quantifying the maximum instance of elasticity for each curve. A 
paired samples t-test confirmed the ratio escalation procedure produced a larger maximum 
change in consumption given the change in unit price than the dose reduction procedure (t (25) = 
4.793, p < 0.05).  
Figure 11. Individual demand curves for rats 8, 14, and 31. 
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Figure 12. The maximum proportional change in 
consumption for both the ratio-escalation and dose-
reduction demand curves for each rat that completed 
all 12 unit price combinations (n=26). 
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2.4 DISCUSSION 
The present study is the first to show that decreasing the dose of nicotine and increasing 
the cost of nicotine do not change behavior in the same way. Across the range of unit prices that 
maintained consumption, rats were more sensitive to manipulations of nicotine dose than to 
manipulations of nicotine cost. However, consumption was not maintained across as many unit 
prices for the ratio escalation manipulation, and across all unit prices the largest instance of 
elasticity was greater for ratio escalation than dose reduction.  
Previous research that suggested manipulations of reinforcer cost and manipulations of 
reinforcer are equivalent manipulations took different analytical approaches than the one taken 
here (Bickel et al., 1990; Bickel et al., 1991; Carroll et al., 1991; Collier et al., 1986; DeGrandpre 
et al., 1993; English et al., 1995; Foster & Hackenberg, 2004; Hursh et al., 1988; Nader et al., 
1993; Sumpter et al., 2004; Woolverton & English, 1997). Previous studies most often 
investigated whether consumption differs at a single unit price when that unit price is created 
using more than one combination. Absence of a significant difference is taken as confirming 
equivalence. The present analysis is consistent with those reports in that it also failed to find a 
significant difference between consumption at two combinations across six unit prices. However, 
more thorough analyses revealed that behavior is not changed in the same way between the two 
manipulations. The present study is the first to investigate the equivalence of cost and reinforcer 
magnitude using nicotine as the reinforcer. It is unclear whether the inequity between nicotine 
cost and nicotine dose is specific to nicotine, or whether a more thorough analysis of other 
reinforcers would reveal inequity for other reinforcers as well. The implications of these findings 
for other drugs of abuse and non-drug reinforcers will be discussed in the General Discussion. 
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However, these data suggest that a more thorough analysis is warranted for previously tested 
reinforcers. 
The difference in consumption between two different FR/dose combinations was 
significantly less than a margin of equivalence at the lowest two unit prices tested. It may be that 
increases in nicotine cost and decreases in nicotine dose change behavior similarly at very low 
unit prices, but at higher unit prices, the two manipulations have different effects. There is some 
support for this hypothesis. Bickel et al. (1990) reanalyzed data from 10 different studies using a 
variety of drugs as reinforcers, and reported that increases in cost and decreases in dose were 
equivalent manipulations, but acknowledged that equivalence was most clear at low unit prices, 
and at high unit prices there was some variability in consumption depending on the FR/dose 
combination used.  
 Across the range of unit prices that maintain consumption, rats were more sensitive to 
manipulations of nicotine dose than manipulations of nicotine cost. The inequity between cost 
and dose over this time period may be the result of differences in the timing of drug delivery. 
Although the ratio between cost and drug delivery is constant at a given unit price, a given 
quantity of nicotine is delivered in a larger bolus over the cost combinations, and is delivered 
over many small boluses for the dose combinations. Many small drug deliveries may have less 
reinforcing value than one large drug delivery, increasing elasticity for dose manipulations.  
Previous nicotine research suggests that the duration over which nicotine is delivered is 
an important determinant in reinforcer value. In one study, rhesus monkeys responded for 
nicotine infusions when nicotine was delivered over 6 s or 24 s, but failed to respond if the 
infusion duration was lengthened to 100 s (Wakasa et al., 1995). Valentine, Hokanson, Matta, 
and Sharp (1997) also reported that nicotine self-administration was not maintained in rats if the 
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infusion duration was longer than 2 or 3 seconds. Wing & Shoaib (2013) showed that nicotine 
self-administration rates dropped sharply when the infusion duration was lengthened from 0.5 s 
to 5 s or 19.5 s, and that the effect was similar to saline substitution. These studies suggest that 
longer infusions durations may not hold equivalent reinforcing value as shorter durations, 
consistent with the hypothesis that rats were more sensitive to decreases in dose because many 
low-dose infusions do not hold the same value as a similar total nicotine dose delivered in a 
single infusion.  
Rats also reached breakpoint at a lower unit price when ratio was escalated than when 
dose was reduced, and the maximum instance of elasticity was greater for ratio-escalation than it 
was for dose-reduction. Combined with the demand analyses, these data indicate that when cost 
is increased, rats are less sensitive to these changes until a breakpoint is reached, and then 
consumption is drastically decreased. The inequity between cost and dose at high unit prices may 
be related to contingencies associated with the cue, which likely functions as a conditioned 
reinforcer because of its previous pairings with nicotine. When ratio is escalated, the cost 
associated with cue delivery is also increased. However, when dose is decreased, a cue is 
delivered along with each smaller drug delivery. The cue has previously been paired with larger 
nicotine doses and likely maintains reinforcement value across conditions, especially given that 
rats only experience four sessions at each combination. Frequent cue delivery may maintain self-
administration at higher unit prices that would otherwise be the case. Other researchers have 
shown that cue delivery can maintain nicotine self-administration when behavior would 
otherwise extinguish (Cohen, Perrault, Griebel, & Soubrie, 2005). Furthermore, it is well 
established that frequent delivery of a conditioned reinforcer combined with infrequent delivery 
of a primary reinforcer (i.e., second-order schedule of reinforcement) can maintain behavior in 
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instances where behavior would not be maintained by the primary reinforcer alone (Kelleher, 
1966).  
Nicotine has also been shown to increase the value of other reinforcing stimuli, including 
stimuli that were previously paired with nicotine delivery (Caggiula et al., 2009; Donny et al., 
2003; Palmatier et al., 2006), an effect known as enhancement. The threshold nicotine dose for 
enhancement has not been established, and it may be that in the present study, low nicotine doses 
increased the value of the cue, which had been previously paired with a higher dose of nicotine, 
maintaining responding for the cue at higher unit prices than maintain responding in the ratio-
escalation combinations where cue delivery is less frequent. 
The cue contingencies in the present study are similar to cue contingencies that would be 
experienced when the price of cigarettes is increased or when nicotine content is decreased. 
When the price of cigarettes is escalated, the cost of the nicotine-associated cues is escalated 
also. However, if nicotine content is decreased, the price of nicotine-associated cues remains 
unchanged. The delivery of these nicotine-associated cues may maintain smoking behavior even 
at low nicotine contents, even though smoking behavior would not be maintained at equivalent 
unit prices created with high nicotine contents and high costs. The value of these cues would be 
expected to decrease with extended experience with low nicotine contents. However, the timeline 
for this change is unclear (Smith et al., 2014).  
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3.0  AIM 2 
3.1 PURPOSE 
The purpose of Aim 2 was to assess whether increases in nicotine cost and decreases in 
nicotine dose change consumption equivalently when very low nicotine doses, below the 
hypothesized threshold for maintaining self-administration behavior, are used. The relationship 
between nicotine dose and nicotine cost may be dependent upon the range of doses tested. 
Researchers have hypothesized that there may be a threshold nicotine dose below which nicotine 
does not function as a primary reinforcer (Benowitz & Hennningfield, 1994; Sofuoglu & 
LeSage, 2012). If nicotine dose is reduced below this threshold, consumption may drop 
drastically even in instances where a unit price approach predicts that consumption would be 
maintained. Thus, the relationship between nicotine cost and nicotine dose below threshold 
cannot be predicted from the relationship between nicotine cost and nicotine dose above 
threshold. If a nicotine reduction policy is enacted, the reduced nicotine content will be one that 
is hypothesized to be below the threshold for maintaining smoking behavior (or maintaining 
nicotine dependence), so the relationship between nicotine cost and very low nicotine doses is 
particularly important to explore. 
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3.2 METHOD 
3.2.1 Subjects 
Male Sprague-Dawley rats (Harlan-Farms, IN) weighing between 200 and 225 g on the 
day after arrival were used as subjects (n=37). All rats were part of a single cohort of rats.  
Housing and feeding conditions were the same as in Aim 1.  
3.2.2 Apparatus 
The same operant chambers were used as in Aim 1. 
3.2.3 Drugs 
 There were no changes from Aim 1, except that after the first unit price manipulation, 
drug was delivered in a volume of 0.05 ml / kg in approximately 0.5 s to allow rats to take more 
infusions within a single session. 
3.2.4 Procedures 
3.2.4.1 Surgery 
For the first five days following surgery, the first cohort of rats had their cannulae flushed 
once daily with a sterile saline solution containing heparin (3 U), timentin (6.67 mg) and 
streptokinase (833.3 U) to maintain catheter patency and prevent infection. After this initial post-
surgery time period, the flushing solution contained only the heparin and timentin. Only data 
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points from rats that passed a patency test consisting of rapid loss of muscle tone to methohexital 
(5 mg/kg i.v.) are included.  
3.2.4.2 General Self-Administration Procedures 
Self-administration procedures, including the time-out and session-length procedures 
were the same as in Aim 1.  
3.2.4.3 Acquisition 
 Rats experienced an increase in FR across sessions to reach the terminal FR used in the 
training condition (FR10). Rats experienced 8 sessions on FR2, 5 sessions on FR5, and 7 
sessions on FR10. Rats then began the unit price portion of the experiment described below.  
3.2.4.4 Unit Price Procedure 
The Unit Price procedure was similar to the Unit Price procedure in Aim 1, except that 
doses 10 times lower than those in Aim 1 were used for the dose-reduction combinations, and 
rats responded on an FR1 for these combinations. Rats each experienced six unit prices, and each 
rat experienced each unit price twice, creating 12 total combinations (Table 2). The first six 
combinations all used the same dose of nicotine, but the number of responses required to earn an 
infusion (FR, cost) increased across unit prices. The second six combinations all required the 
same number of responses to earn an infusion, but the dose of nicotine decreased across unit 
prices. Nicotine doses in this experiment were chosen such that the majority of doses are not 
expected to maintain self-administration behavior (Smith et al., 2014). Rats experienced four 
sessions at each unit price combination, and each rat experienced the combinations in a random 
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order. Rats experienced one session on the training condition (FR10, 60 µg/kg/infusion) in 
between each unit price combination. During the first unit price manipulations, some rats on the  
 
 
Table 2. FR/Dose combinations used in Aim 2. 
 
 
 
low-dose combinations were coming close to emptying the drug syringe in a single session 
(approximately 150 infusions). Starting with the training condition between the first and second 
unit price manipulation, drug solutions were twice as concentrated (nicotine delivered in a 
volume of 0.05 ml/kg) and delivered over half the duration (~0.5 s). On Day 2 of Unit Price 7, a 
rat emptied the drug syringe in a single session (257 infusions), and starting with the following 
session a larger drug syringe was used (10 ml syringe instead of 5 ml), and the infusion speed 
was adjusted. Following completion of all 12 unit price combinations, rats experienced a 13
th
 
condition where they responded on an FR1 for saline along with regular cue conditions (saline + 
cue condition) immediately followed by two sessions where they responded on an FR1 for saline 
without the cue (saline + no cue condition).  
 UNIT PRICE: FR/NICOTINE DOSE (µG/KG/INFUSION) 
 0.133 0.267 0.4 0.533 0.8 1.33 
 FR DOSE FR DOSE FR DOSE FR DOSE FR DOSE FR DOSE 
COST 
ESCALATION 
8 60 16 60 24 60 32 60 48 60 80 60 
DOSE 
REDUCTION 
1 7.5 1 3.75 1 2.5 1 1.875 1 1.25 1 0.75 
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3.2.4.5 Data Analysis  
Analyses were the same as in Aim 1, with one addition. Infusions earned during the 
saline + cue and saline + no cue conditions were compared to infusions earned in the lowest 
nicotine dose condition first using paired samples t-tests, and then using a two one-sided test of 
equivalence.  
3.3 RESULTS 
Although 37 rats were used in the experiment, five rats were excluded from all unit prices 
because of catheter patency. One rat did not earn any infusions on any of the ratio combinations, 
and data have been excluded.  The remaining 31 rats have data that are included for at least some 
unit prices.  
3.3.1 Comparing consumption at each unit price 
Figures 13, 14, and 15 show average and individual consumption across the 12 unit price 
combinations (average last two sessions at each combination). Figure 13 shows consumption 
plotted as two demand curves—one for ratio escalation, and one for dose reduction (error bars 
represent standard error).  
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Consumption only appears similar at the highest unit prices, whereas in Aim 1 consumption was 
qualitatively similar at high and low unit prices. Paired samples t-tests confirmed that 
consumption was significantly different between the two manipulations at the three lowest unit 
prices (0.133: t (28) = 6.909, p < 0.05; 0.267: t (30) = 3.863, p < 0.05; t (31) = 3.113, p < 0.05). 
At the three higher unit prices, consumption failed to meet criteria for a significant difference (ps 
> 0.05), but the difference was also not significantly less than 25% of the mean (0.533: δ = 30.3; 
0.8: δ = 12.5; 1.33: δ = 6.1).  
Figure 13. Average consumption for ratio-escalation and dose-reduction unit price 
combinations. 
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Figure 14. Average and individual consumption data for all 12 unit price combinations with all y-axes on the 
same scale. 
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3.3.2 Comparing increases in cost and decreases in dose when consumption is maintained 
As in Aim 1, a demand analysis was employed to test whether the two manipulations 
changed behavior differently across the range of unit prices that maintained consumption. Data 
points were excluded if consumption fell below 10% of baseline (Figure 16).  
Figure 15. Average and individual consumption data for all 12 unit price combinations with y-axes adjusted for 
each graph. 
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After excluding these data points, 13 rats had two or less data points for at least one of the two 
demand curves, and 18 rats were included in the demand analysis. Figure 17 shows the average 
demand curves for only those data points that were included in the demand curve analysis (error 
bars represent standard error). It represents how average consumption changed over the range of 
unit prices that maintained consumption. The demand curve for ratio-escalation is shifted 
upwards, suggesting that Q0 is likely to differ between the two manipulations.  
  
Figure 16. Proportion of data points excluded from demand curve analysis. 
  47 
 
 
 
 
 
 
 
Equation 1 normalizes both consumption and price for differences in Q0, making it 
possible to test for differences in sensitivity to unit price despite existing differences in Q0. The 
difference in Q0, and the standardization of price in Equation 1 make it difficult to tell from the 
demand curve shown in Figure 17 whether there is a difference in sensitivity to unit price. Figure 
18 is a graphical representation of average demand once consumption and price have been 
normalized for Q0. In this figure, it appears that dose is more sensitive than ratio to 
manipulations of unit price across the majority of unit prices tested.  
Figure 17. Average consumption for ratio-escalation and dose-reduction unit price 
combinations including only data points that were included in demand analysis. 
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R
2
 values for both sets of demand curves are shown in Figure 19. While there were a few 
low R
2
 values, fits were generally good, and there was not a significant difference between ratio-
escalation or dose-reduction curves (p > 0.05).  
 
 
 
 
 
 
Figure 18. Average demand after normalizing consumption and price for Q0. 
Figure 19. R
2
 values for the best 
fitting functions of Equation 1 
for 28 rats included in demand 
analysis. 
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Figure 20. Free parameters Q0 (a) and α (b) from best fitting functions of Equation 1. 
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Figure 20 shows free parameters from the best fitting functions of Equation 1 for both Q0 and α. 
Q0 was higher for ratio-escalation than dose reduction, and α was lower for ratio-escalation than 
dose-reduction (Q0: t (17) = 4.084, p < 0.05; α: t (18) = 6.919, p < 0.05). Parameters from ratio-
escalation and dose-reduction curves were not significantly correlated with each other (Figure 
21, ps > 0.05), suggesting that an individual’s response to one manipulation is a poor predictor of 
their response to the other manipulation.  
 
  
Figure 21. Correlation between free parameters Q0 (a) and α (b). 
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3.3.3 Comparing increases in cost and decreases in dose when consumption is not 
maintained 
Breakpoint was calculated for 26 rats that completed all 12 unit price combinations, and 
had at least one unit price for both curves at or above baseline consumption (Figure 22). A 
Wilcoxon Signed Ranks test failed to reveal significant differences between the two 
manipulations (p > 0.05). However, the breakpoint for dose was higher than the breakpoint for 
ratio for 14 rats, the same for both manipulations for eight rats, and higher for ratio than for dose 
for 4 rats.  
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As in Aim 1, the maximum instance of elasticity was compared for the ratio-escalation and dose-
reduction curves (Figure 23). The maximum decrease was larger for the ratio-escalation 
manipulation than for the dose-reduction manipulation (t (25) = 4.518, p < 0.05). 
 
Figure 22. Break point unit prices for each of the 26 rats that completed all 12 unit 
prices. 
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Figure 23. The maximum proportional change in 
consumption for both the ratio-escalation and dose-
reduction demand curves for each rat that completed 
all 12 unit price combinations (n=26). 
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3.3.4 Saline conditions 
 The number of infusions earned in the final two saline conditions (saline + cue, saline + 
no cue) was compared to the number of infusions earned for the lowest dose condition (Figure 
24). Paired samples t-tests failed to reveal a significant difference between the saline + cue 
condition, but infusions earned in the saline + no cue condition were significantly less than 
infusions earned in the lowest nicotine dose condition (t (24) = 2.776, p < 0.05). The difference 
in infusions between the lowest nicotine dose condition and the saline + cue condition was not 
significantly less than 25% of the overall mean (p > 0.05, δ=9.59). 
  
Figure 24. Average infusions earned over the last two 
sessions of the lowest dose tested in the set of dose-reduction 
combinations, the saline + cue condition, and the saline + no 
cue condition. 
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3.4 DISCUSSION 
The present study showed that when very low nicotine doses are used, increases in 
nicotine cost and decreases in nicotine dose are not equivalent manipulations. Consistent with 
Aim 1, rats were more sensitive to decreases in dose than they were to increases in cost. 
Breakpoints were not significantly different, but the maximum decrease in consumption 
experienced across unit prices was larger for ratio escalation than for dose reduction. 
Furthermore, ratio-escalation curves had higher Q0 values than dose-reduction curves.  
Q0 is a free parameter estimating consumption if the reinforcer were free, so higher Q0 
values for ratio-escalation suggest that even if doses in the range used for the dose-reduction 
curve in the present study were made freely available, rats would take less nicotine than if the 
dose used in the ratio-escalation curve was made free available.  
Breakpoints were not significantly different between ratio-escalation and dose-reduction, 
but more rats did have higher dose breakpoints than ratio breakpoints (14 vs. 4 rats), and the 
largest proportional decrease in consumption across unit prices was greater for ratio-escalation 
than dose-reduction. The high rate of cue delivery for dose-reduction combinations may prevent 
large changes in consumption when unit price is increased, as discussed in Aim 1.  
Evidence that the cue was important in maintaining self-administration behavior at low 
nicotine doses also comes from the final two saline conditions. Infusions earned in the saline + 
cue condition did not differ from infusions earned for the lowest dose of nicotine, suggesting that 
responding at the lowest nicotine dose may be mostly maintained by the cue. Furthermore, the 
number of infusions earned in the saline + no cue condition was significantly lower than the 
number of infusions earned in the lowest nicotine dose condition (0.75 µg/kg/infusion + cue). 
However, several methodological limitations make it difficult to draw conclusions about the role 
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of the cue from these data. The presentation of the two saline conditions was confounded with 
the number of sessions since the last nicotine exposure (all rats received the saline + cue 
condition first with no training condition in between), and rats only experienced two sessions of 
the saline + no cue condition. Unfortunately, the second session of the saline + no cue condition 
occurred on December 23
rd
, 2014, and further experimental testing was not possible. 
Furthermore, the difference in infusions for the low nicotine dose + cue condition and the saline 
+ cue condition was not significantly less than a reasonable margin of equivalence (25% of 
overall mean), so it is not possible to conclude that responding at the lowest nicotine dose was 
entirely cue maintained.  
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4.0  AIM 3 
4.1 PURPOSE 
 The purpose of Aim 3 was to directly evaluate the hypothesis that consumption at a 
single unit price should be equivalent regardless of the combination used to create that unit price. 
The best challenge to this hypothesis is to incorporate some combinations that use very low 
nicotine doses that may be below the threshold for maintaining self-administration behavior. 
Using data from Aims 1 and 2, a unit price of 0.533 was chosen. Lower unit prices would not 
have allowed for doses as low as 1.875 µg/kg/infusion and 3.75 µg/kg/infusion to be included. 
Higher unit prices may not have maintained self-administration behavior. Because the role of the 
cue in maintaining self-administration at low nicotine doses is uncertain, one combination was 
included where rats had the opportunity to respond on an FR1 for saline alone with the cue.  
4.2 METHOD 
4.2.1 Subjects 
Male Sprague-Dawley rats (Harlan-Farms, IN) weighing between 200 and 225 g on the 
day after arrival were used as subjects (n=42).  Data are pooled from two cohorts of rats that 
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completed the experimental procedures at separate times. Housing conditions were the same as 
in Aim 1. 
4.2.2 Apparatus 
The same operant chambers were used as in Aim 1. 
4.2.3 Drugs 
 There were no changes from Aim 1, except prior to the start of the unit price 
manipulation, the concentration of drug was increased to allow rats to earn more infusions in a 
single session. Across all unit price manipulations, drug was delivered in a volume of 0.05 ml 
/kg/infusion delivered in approximately 0.5 s. 
4.2.4 Procedures 
4.2.4.1 Surgery 
The antibiotic used in the flushing solution varied across the two cohorts. The first cohort 
of rats had their cannulae flushed once daily with a sterile saline solution (0.1 ml) containing 
heparin (3 U), timentin (6.67 mg) and streptokinase (833.3 U) to maintain catheter patency and 
prevent infection for the first five days following surgery. After this initial post-surgery time 
period, the flushing solution contained only the heparin and timentin. Prior to the start of self-
administration, timentin became unavailable and 10mg cefazolin was substituted. The second 
cohort of rats received 10 mg cefazolin as the antibiotic during acquisition, but prior to the start 
  59 
of the unit price manipulation, the lab switched to gentamicin (1mg). Only data points from rats 
that passed a patency test consisting of rapid loss of muscle tone to methohexital (5 mg/kg i.v.) 
are included.  
4.2.4.2 General Self-Administration Procedures 
Self-administration procedures, including the time-out and session-length procedures 
were the same as in Aim 1.  
4.2.4.3 Acquisition  
All rats experienced an increase in FR across sessions to reach the terminal FR used in 
the training condition (FR10), and drug was delivered in a volume of 0.05 ml/kg/infusion using 
10 ml syringes for all unit price manipulations. However, the two cohorts of rats differ in the 
number of sessions spent at each FR during acquisition, and in how the final drug concentration 
was reached. The first cohort of rats used 10-ml syringes throughout the experiment. At the start 
of acquisition, rats responded on an FR2 schedule of reinforcement for eight days using the more 
concentrated nicotine solution (0.05 ml/kg/infusion), delivered using 10-ml syringes. However, 
responding and earned infusions were low, and we hypothesized that the highly concentrated 
solution was interfering with rats learning to respond for nicotine. The solution was diluted to the 
lab standard concentration (0.1 ml/kg/infusion) for five sessions while rats continued on an FR2, 
and rates of responding increased. The FR was then increased across sessions (FR5 for six 
sessions, FR10 for eight sessions). The concentration of the solution was then increased again, 
and infusions were unchanged, suggesting that the more concentrated solution interferes during 
initial acquisition only. Rats remained on an FR10 with the more highly concentrated solution 
for six sessions before beginning the unit price manipulations. The second cohort of rats started 
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acquisition on an FR2 schedule of reinforcement with drug delivered in the more dilute volume 
of 0.1 ml/kg/infusion using 5-ml syringes in order not to interfere with learning nicotine 
administration. The FR was then escalated (FR2 for 18 sessions, FR5 for six sessions, FR10 for 
five sessions) before the drug syringe was changed to allow rats to earn more infusions within a 
single session (10 ml syringes for five sessions) and the drug concentration was increased for the 
same reason (0.05 ml/kg/infusion for 6 sessions). The unit price manipulation then began.  
4.2.4.4  Unit Price Procedure 
 The Unit Price procedure was similar to the Unit Price procedure in Aim 1, except that 
seven of the eight FR/dose combinations used create equivalent unit prices, allowing for a direct 
test of the hypothesis that consumption will be equivalent at equivalent unit prices, regardless of 
the combination used to create that unit price. The eighth combination involved rats responding 
for saline + the cue, and was added to investigate the role of the cue in maintaining self-
administration at the lowest dose combinations used. Combinations are shown in Table 3.  
 
 
 
 
 
 
 
 
As in the first two experiments, rats experienced four sessions at each combinations, 
experienced the combinations in a random order, and a single training condition session was 
UNIT PRICE = 0.533 
FR DOSE 
(µG/KG/INFUSION) 
1 SAL 
1 1.875 
2 3.75 
3 5.625 
4 7.5 
12 22.5 
24 45 
32 60 
Table 3. FR/Dose combinations used in 
Aim 3. 
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inserted between each combination. Due to an error, rats only experienced three sessions on the 
seventh unit price combination, and on the third session two of the rats were switched in the 
operant chambers and experienced the other rat’s experimental condition for that session. The 
data points for those two rats from the seventh combination have been excluded, and for the 
remaining rats consumption at the second and third combination was averaged for data analysis. 
Average consumption at the seventh combination appears consistent with remaining data points 
gathered at other combinations using the third and fourth session. 
4.2.4.5 Data Analysis  
 Data analysis focused on testing whether consumption was equivalent across the seven 
unit price combinations. Planned comparisons tested whether each combination was different 
from the highest and lowest dose combination using paired-sample t-tests. In the case of 
nonsignificant t-tests, two-one sided tests of equivalence tested whether the difference was less 
than 25% of the mean of those two combinations.  
4.3 RESULTS  
Of the 42 rats used in Aim 3, 13 rats failed the first patency test conducted, and all data 
from these rats has been excluded. One rat failed a final patency test, but had passed an earlier 
one, and data from the last passed patency have been included.  Five rats earned less than two 
infusions at baseline (average of last two training condition sessions) and have been excluded 
from all analyses. 
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 Figure 25 shows consumption across the seven unit price combinations (saline excluded 
because consumption cannot be plotted).  Qualitatively, there appears to be an inverted-U shape 
to the graph, such that consumption increases across the first few combinations, is high for the 
middle combinations, and then is lower at the highest dose combination. Paired samples t-tests 
using FR1/1.875 µg/kg/infusion as the reference group revealed that consumption was 
significantly greater at FR2/3.75, FR3/5.625, FR4/7.5, and FR12/22.5 combinations (represented 
by *, FR2/3.75: t(23) = 3.92, p < 0.05; FR3/5.625: t (23) = 5.364, p < 0.05; FR4/7.5: t(22) = 
4.765, p < 0.05; FR12/22.5: t (23) = 4.890, p < 0.05). Consumption at the other two 
combinations did not meet criteria for a significant difference, and the difference was also not 
significantly less than 25% of the mean (δ) (FR24/45: δ=35.33; FR32/60: δ=30.38). Paired 
samples t-tests using FR32/60 as the reference group revealed that consumption was significantly 
greater at FR3/5.625 and FR12/22.5 combinations (represented by **, FR3/5.625: t(24)=2.215, p 
< 0.05; FR12/22.5: t(23) = 2.724, p < 0.05), but did not meet criteria for a significant difference 
at the other combinations, and the difference was also not significantly less than 25% of the 
mean (δ) (FR1/1.875: δ = same as above; FR2/3.75: δ=37.14; FR4/7.5: δ=39.58; FR24/45: 
δ=36.89).   
  
Figure 25. Consumption at each of seven combinations that form the same 
unit price (0.533). 
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 Figure 26 shows the average number of infusions earned at each of the eight 
combinations. A paired-samples t-test confirmed that rats earned significantly more infusions at 
the FR1/1.875 µg/kg/infusion combination than at the FR1/saline combination (t(21)=3.907, p < 
0.05). Differences between other combinations were not tested because the FR varies across 
combinations, making other differences difficult to interpret. 
 
 
4.4 DISCUSSION 
 The results from Aim 3 show that consumption is not equivalent at a single unit price 
regardless of the cost/dose combination used to create that unit price. Qualitatively, consumption 
appeared to be low when low FR/dose and high FR/dose combinations were used, but higher 
across a middle range of FR/dose combinations. When a low FR and dose was used (FR1/1.875), 
Figure 26. Infusions earned across eight combinations. 
  64 
consumption was significantly less than four other combinations that employed higher FRs and 
doses, and consumption at the highest FR and dose combination used (FR32/60) was 
significantly lower than consumption at two combinations. These data are inconsistent with the 
behavioral economics hypothesis that consumption should be equivalent at a single unit price 
regardless of the combination used to create that unit price. 
 Infusions earned at the FR1/1.875 combination were significantly greater than infusions 
earned at the FR1/Saline condition, suggesting that the cue is not solely responsible for 
consumption at the FR1/1.875 combination. It is unclear whether responding at the FR1/1.875 
combination is maintained by the primary reinforcing or reinforcement enhancing effects of 
nicotine. Previous data from our lab (Smith et al., 2013) has shown that the threshold nicotine 
dose for maintaining self-administration behavior is between 3.75 µg/kg/infusion and 7.5 
µg/kg/infusion, but in the present study 1.875 µg/kg infusion maintained self-administration 
significantly above saline. The procedure used in our previous paper was different in that 
threshold was evaluated using an FR5 schedule of reinforcement, the time-out following each 
infusion was 1-min instead of 3-s, and the session length was fixed at one hour. The decreased 
FR and shortened time out likely contributed to a higher threshold nicotine dose required for 
maintaining behavior. If the threshold nicotine dose for maintaining behavior is shifted by time-
out, that suggests that several small nicotine infusions can be earned in a row, creating a bolus 
large enough to maintain behavior at a lower dose than would otherwise be possible. However, 
data from Aims 1 and 2 suggest that while several infusions in a row may create a bolus large 
enough to maintain behavior, they may be extended over too long a period to be of equal value 
as that same bolus delivered over a short period. If the threshold nicotine dose for maintaining 
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behavior is shifted by FR, these data are consistent with the behavioral economics hypothesis 
that cost is important in determining whether or not behavior will be maintained.  
 Another possibility is that consumption is increased because a small dose of nicotine 
enhances the value of the nicotine-associated cue. Previous research has shown that nicotine non-
contingently enhances the value of other reinforcers in the environment (Caggiula et al., 2009; 
Donny et al., 2003; Rupprecht et al., 2015). The cue conditions used in the present study have 
been paired with nicotine across many sessions. While 1.875 µg/kg/infusion may be below the 
threshold for primary reinforcement, it may be above threshold for the reinforcement enhancing 
effects of nicotine. Increased infusions at the FR1/1.875 combination may then reflect an 
increased value of the cue rather than responding for the nicotine per se. The experimental 
procedures here make it impossible to dissociate the primary reinforcing and reinforcement 
enhancing effects of the low nicotine dose.  
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5.0  GENERAL DISCUSSION 
5.1 SUMMARY 
 The studies reported in this dissertation show that increasing nicotine cost and decreasing 
nicotine dose are not equivalent manipulations. Behavior was more sensitive to decreases in the 
dose of nicotine than to increases in the cost of nicotine. The largest decrease in consumption 
across all unit prices was greater for ratio escalation. When above threshold doses were used, 
behavior was maintained across a smaller range when cost was increased than when dose was 
decreased. The results of Aim 3 confirm that consumption is not equivalent at a single unit price 
regardless of how that unit price is created. Consumption is significantly lower at low FR/dose 
and high FR/dose combinations than at combinations with moderate FRs and moderate doses. 
Together, these results suggest that increases in the cost of a reinforcer and decreases in the 
magnitude of a reinforcer do not change behavior in the same way, and are not manipulations of 
the same factor, unit price. 
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5.2 BEHAVIOR IS MORE SENSITIVE TO DECREASES IN DOSE THAN TO 
INCREASES IN COST 
 It is unclear why rats are more sensitive to decreases in dose than to increases in cost 
across the range of prices that maintain behavior. One possibility is that the pharmacological 
effect of several small doses is not equivalent to one large dose of nicotine, even if they total the 
same total drug consumption. A series of small drug infusions differ in the overall rate of drug 
delivery, the volume of vehicle, and the pattern of delivery (continuous versus a series of 
infusions interspersed with breaks), any of which could result in a different pharmacological 
effect than a larger continuous bolus.  
There is substantial evidence that the rate of drug delivery may be a critical factor in 
producing any given pharmacological effect, and especially in functioning as a primary 
reinforcer. The majority of previous research suggests that nicotine is less likely to maintain 
behavior when delivered over a longer duration. Wing and Shoaib (2013) showed that a dose of 
nicotine near the peak of the dose-response curve (30 µg/kg/infusion) only maintained behavior 
when it was delivered over a relatively short duration (0.5 and 1.0 s), and not when that duration 
was extended (5 s or 19.5 s). Another study showed that rhesus monkeys only self-administered 
nicotine when the infusion duration was short, but not when it was extended (Wakasa et al., 
1995). Furthermore, the highly addictive nature of cigarettes is often attributed to the high rate of 
drug delivery associated with the route of administration (Benowitz, 1990). In contrast to these 
studies, one study showed that infusion duration had no effect in mice (Fowler & Kenny, 2011), 
and another study showed that rats self-administered lower doses of nicotine than previously 
thought possible when the infusion duration was lengthened (Sorge & Clarke, 2009).  
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The impact of infusion duration may apply more broadly to all drugs of abuse. Rapid 
drug delivery has been shown to increase the subjective effects of all drugs of abuse (Abreu, 
Bigelow, Fleisher, & Walsh, 2001; Marsch et al., 2001; Nelson et al., 2006). Rats have also been 
shown to escalate cocaine intake when infusions are delivered rapidly, but not when infusions 
are delivered slowly (Wakabayashi et al., 2010), and faster infusion durations maintain higher 
response rates in self-administration procedures (Balster & Schuster, 1973; Panlilio et al., 1998). 
Oxycodone has been shown to support self-administration in humans when it is delivered over a 
short duration as opposed to a long duration (Comer et al., 2009). Because the duration of drug 
delivery appears to be an important variable across multiple drugs abuse, the increased 
sensitivity of behavior to nicotine dose over nicotine cost may apply more broadly to other drugs 
of abuse. 
Faster infusion durations may promote higher rates of drug self-administration through 
differences in pharmacokinetics or pharmacodynamics, or in differences in learning the 
contingency. A faster rate of cocaine delivery has been shown to produce a shorter time to peak 
concentration, but similar peak concentration, and similar concentrations several minutes after 
injection (Panlilio et al., 1998). These effects were similar when brain concentrations of cocaine 
were measured. The difference in time to peak drug concentration may affect brain areas that are 
involved in reward. Researchers have shown that shorter infusion durations increase c-fos and 
arc activation in the nucleus accumbens core and shell, and increase the inhibition of re-uptake 
of dopamine release in the nucleus accumbens core (Samaha, Mallet, Ferguson, Gonon, & 
Robinson, 2004). Woolverton and Wang (2004) also reported that shorter infusions increased the 
rate of dopamine transporter binding. A longer duration of reinforcer delivery may also function 
as a delay between the end of the response requirement and delivery of the reinforcer. Research 
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has shown that long delays in reinforcer delivery can interfere with learning a contingency, and 
may decrease responding for the reinforcer (Lattal, 2010).  
While the duration of reinforcer delivery has not been investigated with reinforcers that 
are not drugs of abuse, there is some evidence that the timing of reinforcer delivery is an 
important variable even when the reinforcer is not a pharmacological drug. It is well established 
that a reinforcer loses subjective value as the delay to reinforcer delivery is increased, a 
phenomenon known as delay discounting (Bickel, MacKillop, Madden, Odum, & Yi, 2015; 
Madden, Begotka, Raiff, & Kastern, 2003). Rats will choose a shorter delay for food reward over 
a longer delay (Schindler et al., 2009). However, it is unclear whether a large reinforcer 
delivered after a delay (e.g., after completing a large FR) would have more subjective value than 
a reinforcer delivered in small increments that extend over a long delay. For example, would 
people choose to have $80 delivered after 80 days instead of $1/day for 80 days? It seems likely 
that people would choose to wait and receive the $80. Thus, it is unclear whether the increased 
sensitivity to dose reduction observed here would extend to non-drug reinforcers.  
5.3 BREAKPOINT IS LOWER FOR RATIO ESCALATION THAN DOSE 
REDUCTION WHEN ABOVE-THRESHOLD NICOTINE DOSES ARE USED 
In Aim 1 when above-threshold nicotine doses were used, the unit price that maintained 
consumption was lower for ratio-escalation than for dose-reduction. While there was not a 
significant difference between breakpoints in Aim 2, there was a trend such that more rats had 
lower breakpoints for ratio-escalation than for dose-reduction (14 rats had higher dose 
breakpoints, only four had higher ratio breakpoints). Furthermore, in both Aims 1 and 2, the 
  70 
maximum instance of elasticity was larger for ratio-escalation than dose-reduction. Together, 
these results suggest that when cost is escalated, rats will reach a sudden breakpoint and 
consumption will drop drastically, whereas when dose is decreased rats reach a breakpoint later.  
The ability of lower nicotine doses to maintain consumption at higher breakpoints may be 
related to differences in cue delivery. In the procedure used here, the cue light was delivered 
along with each nicotine infusion, so when dose is decreased, rats continue to receive frequent 
cue delivery. However, when cost is escalated, the cue is delivered less frequently because more 
responses are required to produce it. The cue likely has value because of its prior pairing with 
nicotine delivery (Pavlov, 1927). Thus, frequent cue delivery in the dose-reduction combinations 
may have maintained behavior at unit prices where behavior would not have been maintained by 
nicotine alone. Previous research has shown that nicotine-associated cues can maintain behavior 
for at least 55 sessions following substitution of saline for nicotine (Cohen et al., 2005). 
Responding for the cue is also likely impacted by reinforcement enhancement. Previous 
research from our lab has shown that nicotine can noncontingently increase the value of 
reinforcers (Caggiula et al., 2009; Donny et al., 2003; Rupprecht et al., 2015). The enhancement 
is synergistic in that responding for nicotine + a cue is usually higher than responding for the cue 
alone and responding for nicotine alone added together. Thus, as nicotine dose is decreased, rats 
may continue to respond for a nicotine + cue combination because the low dose of nicotine has 
increased the value of the cue reward.  
A lack of reinforcement enhancement may be the reason that the difference in 
breakpoints was less drastic in Aim 2. The dose-response relationship for nicotine dose and 
reinforcement enhancement is untested. Unpublished research from our lab has shown that there 
is a threshold nicotine dose for reinforcement enhancement, and increasing the nicotine dose 
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above that threshold does not result in a larger degree of enhancement. However, in this 
unpublished study nicotine was delivered subcutaneously, so it is not possible to determine 
which doses used in Aims 1 and 2 are above the threshold for reinforcement enhancement. If low 
doses of nicotine used in Aim 2 are not above threshold for reinforcement enhancement, then 
responding at very low nicotine doses may be only maintained by the secondary reinforcing 
characteristics of the cue along with any primary reinforcing characteristics of the low nicotine 
dose. 
Although the inequity in cue delivery makes it impossible to assess whether breakpoints 
would have been similar for ratio escalation and dose reduction if the cue were removed, the 
present procedure in which the cue is delivered along with each infusion more closely models 
reinforcer delivery in the natural environment. Reinforcers are delivered in the context of other 
stimuli, which often take on reinforcing value (Conklin & Tiffany, 2002). When the magnitude 
of each reinforcer delivery is decreased, the presence of other stimuli is unlikely to change, so it 
is important to assess the equivalence of cost escalation and dose reduction in this context. If the 
magnitude of the reinforcer is decreased enough, extinction should take place and the cue should 
cease to have reinforcing value. The four sessions at each combination used in the present studies 
are likely not enough for extinction, so the studies here most closely resemble a scenario where 
extinction is not yet complete.  
Cue delivery in the present set of experiments also more closely models a scenario of 
relevance for nicotine reduction. If a nicotine reduction policy is implemented, non-nicotine cues 
will continue to be delivered along with each smaller delivery of nicotine (Donny et al., 2012). 
For example, the taste and feel of a cigarette will continue to be paired with each puff of smoke 
even though the nicotine yield within each puff will be lower. However, when the price of 
  72 
cigarettes is increased, the nicotine-paired cues are only delivered along with each nicotine 
delivery after the full cost has been paid (Smith et al., 2014). Thus, the cue conditions arranged 
in the present experiment are most appropriate for assessing the equivalence between cost 
escalation and dose reduction. 
5.4 CONSUMPTION IS NOT EQUIVALENT ACROSS MULTIPLE 
COMBINATIONS OF THE SAME UNIT PRICE 
Aim 3 showed that consumption is not equivalent at a single unit price regardless of the 
FR/dose combination used to create that unit price. These results conflict with predictions made 
by a behavioral economics framework that consumption is a function of unit price, and the FR or 
dose used for that unit price is not relevant. 
Because FR and dose vary together in Aim 3, it is impossible to determine which factor is 
responsible for decreased consumption at low FR/dose and high FR/dose combinations. 
However, previous literature can provide some hypotheses. Low consumption at low FR/dose 
combinations is likely the result of decreased reinforcing value of low nicotine doses. Previous 
self-administration studies have shown that very low nicotine doses (1.875 and 3.75 
µg/kg/infusion) produce lower responding than higher nicotine doses at the same FR (Smith et 
al., 2013), consistent with the interpretation that in Aim 3 low nicotine doses used in some 
combinations produced lower consumption. Also consistent with that hypothesis, consumption 
for a given dose of nicotine is generally higher when low FRs are used (Donny et al., 1998), 
making it unlikely that the low FRs used in these combinations are responsible for decreased 
consumption. 
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Low consumption at high FR/dose combination is likely the result of high FRs used in 
these combinations. Previous studies have shown that when nicotine dose is increased and FR is 
held constant, consumption increases (Donny et al., 1999; Donny et al., 2000). Thus, it is 
unlikely that the high doses contributed to decreased consumption in high FR/dose combination. 
However, it is well known that high FRs produce lower levels of consumption. Thus, it is likely 
that low FR/dose combinations produce lower consumption because of the low doses used, and 
high FR/dose combinations produce lower consumption because of the high FRs used.  
5.5 PREVIOUS INVESTIGATIONS OF EQUIVALENCE BETWEEN REINFORCER 
COST AND REINFORCER MAGNITUDE 
 The present studies are the first to show that increases in the cost of a reinforcer and 
decreases in the magnitude of a reinforcer are not equivalent manipulations. There are several 
differences between this investigation and previous investigations in the analytic strategy that 
was employed. This investigation used a more rigorous strategy that previous investigations. 
First, this is the first set of studies to evaluate the two manipulations by fitting demand curves to 
consumption produced by the two manipulations. The majority of previous investigations have 
used the strategy undertaken in Aim 3—assessing whether consumption is the same at a given 
unit price regardless of the cost/dose combination used to assess it. Second, this is the first set of 
studies to require that consumption meet a margin of equivalence rather than to accept that no 
significant difference signified equivalence. Third, this is the first set of studies to compare 
breakpoints or the maximum instance of elasticity between the two manipulations.  
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 The present studies are also the first to investigate this research question by directly 
manipulating nicotine. The majority of previous investigations have investigated other 
reinforcers. One other previous report has investigated this research question using human 
smokers by manipulating the number of cigarette puffs that could be earned (Bickel et al., 1991). 
However, manipulating the number of cigarettes puffs also manipulates non-nicotine cigarette 
constituents that may contribute to reinforcing value. Furthermore, manipulating the number of 
cigarette puffs manipulates delivery of nicotine-paired cues. In the present procedure, the 
magnitude of the cue was not directly manipulated, which may have contributed to the inequity 
between cost and dose observed here. 
5.6 IMPLICATIONS FOR BEHAVIORAL ECONOMICS 
 The present results conflict with a fundamental assumption of the behavioral economics 
approach. Behavioral economics posits that sensitivity to unit price is a measure of “essential 
value,” a construct that is inherent to any given reinforcer and can be used to compare reinforcers 
(Hursh & Roma, 2013; Hursh & Silberberg, 2008). The present results suggest that sensitivity to 
cost and sensitivity to dose are not equivalent, and therefore cannot be measures of the same 
construct, essential value.  
 The construct of “essential value” as measured by sensitivity to unit price has been 
posited as a measure drug abuse liability, and as an index if dependence (Bentzley et al., 2014; 
Hursh & Silberberg, 2008). The majority of previous research validating sensitivity to unit price 
as a measure of essential value has manipulated cost and held reinforcer magnitude constant 
(Hursh & Silberberg, 2008). Thus, it seems likely that for any reinforcer, sensitivity to cost may 
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be useful as an indicator of reinforcer value or even of dependence for drug reinforcers. 
Manipulations of reinforcer magnitude have not been validated as predicting constructs that 
might be associated with reinforcer value or drug dependence. 
Fits of Equation 1 were good for both manipulations of nicotine cost and nicotine dose, 
suggesting that consumption is changed exponentially by both increases in nicotine cost and 
decreases in nicotine dose. These data suggest that behavioral economics may still provide useful 
tools for assessing how behavior is changed by both manipulations of cost and magnitude. 
Demand curves may by useful for understanding the relationship between consumption and 
either cost or reinforcer magnitude. Equation 1 may be useful for quantifying how consumption 
is changed by each manipulation. However, researchers should be wary of interpreting 
parameters as measures of any construct, and cannot make inferences about one manipulation 
based on information about the other manipulation. 
5.7 IMPLICATIONS FOR NICOTINE REDUCTION 
These data suggest that smoking behavior will not be changed in the same way when 
nicotine content is reduced as when the price of cigarettes is increased. Furthermore, an 
individual’s sensitivity to changes in the price of cigarettes will be a poor predictor of that 
individual’s sensitivity to decreases in the content of nicotine within a cigarette. However, we 
may be able to use information about the relationship between increasing cost and decreasing 
dose to provide us with some information about changes in behavior as a function of nicotine 
content.  
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Nicotine consumption is likely to be more sensitive to changes in nicotine content than to 
changes in the cost of cigarettes, at least over the range of prices that maintain smoking behavior. 
Prior research on cigarette taxation suggests that for every 10% increase in the price of 
cigarettes, there is a 4% reduction in cigarette consumption (Chaloupka & Warner, 1999). Thus, 
the ratio of the change in nicotine consumption to the change in nicotine content is likely to be 
greater than 0.4 for above-threshold nicotine contents.  
The primary objective of nicotine reduction is to reduce the prevalence of smoking—or 
to reduce nicotine content beyond the unit price that maintains behavior. Results from these 
studies showed that when very low doses were used, there was a trend towards breakpoints being 
higher for the dose-reduction manipulation than for the ratio-escalation manipulation. However, 
this difference was not significant, so breakpoints for dose-reduction may be similar to or even 
higher than breakpoints for ratio-escalation. One study evaluated breakpoint for the price of 
cigarettes using a hypothetical purchase task in which participants estimated the number of 
cigarettes they would smoke if cigarettes were a variety of prices (MacKillop et al., 2012). 
Participants in these studies reported mean breakpoints of $3.49-$4.88 per cigarette for their 
usual brand cigarette depending on the cue conditions and the time since they had smoked. 
Assuming usual brand cigarettes yield approximately 1 mg of nicotine, and an average pack of 
cigarettes in the US is $6.36 (31.8 cents per cigarette) (World Lung Foundation & American 
Cancer Society, 2012) a unit price approach would estimate the threshold nicotine yield to be 
between 0.065 mg and 0.091 mg, depending on deprivation and cue conditions. Based on results 
presented in this dissertation, we would expect the breakpoint yields to be in that range or even 
lower. These values are consistent with previous research indicating the threshold nicotine yield 
may be between 0.05 and 0.1 mg (Donny & Jones, 2009; Hatsukami, Kotlyar, et al., 2010). 
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Finally, the results from Aim 3 suggest that very low doses and very high costs are likely 
to suppress consumption more than moderate doses and costs that create the same unit price. 
Thus, the most effective method for suppressing consumption is likely to combine very low 
nicotine content with very high costs. Nicotine reduction is likely to be most effective when 
combined with other tobacco control interventions that increase the cost of obtaining cigarettes.  
5.8 FUTURE DIRECTIONS 
Future studies should assess the generalizability of these results to other reinforcers. The 
present study suggests that increasing the cost of nicotine and decreasing the dose of nicotine are 
not equivalent manipulations. However, it is unclear whether the discrepancy between these 
results and equality found in previous studies is the result of differences in analytic strategy or 
differences in the reinforcer investigated. The present studies were the first to conduct a thorough 
analysis of how consumption is changed as a function of the two manipulations, and the first to 
directly manipulate nicotine.  
It may also be beneficial to assess the role of cue-maintained responding in the 
relationship between increasing the cost of nicotine and decreasing the dose of nicotine. While 
the present experiments arranged the cue such that the results would be most relevant to the 
“natural environment,” the underlying assumption of behavioral economics does not include a 
drug-paired cue that is delivered frequently for one manipulation and infrequently for the other 
manipulation. Thus, it may be beneficial to understand the role of the cue, if any, in the inequity 
seen in these experiments. 
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Future studies may examine whether the relationship between increasing nicotine cost 
and decreasing dose would be equivalent under other conditions. For example, a 3-s time out was 
employed in the present studies to prevent rats from taking a dangerous quantity of nicotine. 
However, the time-out may have played a critical role in the inequity between increasing cost 
and decreasing dose because rats were unable to earn infusions immediately following one 
another. Behavioral economics procedures are also typically conducted under extended access 
conditions, where the session is not limited by time. The present procedure allowed all rats to 
have two hours within the session to respond. Thus, it may be useful to assess whether increasing 
reinforcer cost and decreasing reinforcer magnitude are equivalent manipulations under 
extended-access conditions. However, even when session length is uncapped, time-outs are 
generally used following each infusion, creating an inequity between cost and dose because rats 
will have less time in a day to respond when dose is reduced than when cost is increased. The 
present procedure, in which session time is variable but the total duration of time-in is fixed, may 
actually allow cost and dose to be more equivalent than traditional procedures. Another potential 
avenue for future research is whether the two manipulations would have been equivalent, or 
closer to equivalent, if nicotine was manipulated through changes in the length of earn infusion 
instead of concentration of the nicotine solution. In this case, duration of nicotine delivery would 
have differed less between the two manipulations when consumption was equal, although it still 
would have differed by the length of time required to complete the FRs in the dose-reduction 
manipulation. However, the procedure used here where concentration of nicotine solution was 
manipulated is more relevant to nicotine reduction, where the concentration of nicotine within 
tobacco and within cigarette smoke will be reduced.  
  79 
5.9 CONCLUSIONS 
The present set of studies showed, for the first time, that increases in the cost of nicotine 
and decreases in the dose of nicotine are not equivalent manipulations. Rats were more sensitive 
to manipulations of nicotine dose than nicotine cost over the range of unit prices that maintain 
behavior, but when cost was increased rats reached a breakpoint at a lower unit price than when 
dose is reduced, and the maximum instance of elasticity was larger was ratio-escalation. 
Differences in the duration of nicotine delivery may have contributed to increased sensitivity to 
nicotine dose across a range of unit prices, and differences in cue delivery may have contributed 
to differences seen in breakpoint and in the maximum instance of elasticity. When very low 
nicotine doses were used for the dose-reduction manipulation, increases in nicotine cost and 
decreases in nicotine dose are still not equivalent manipulations, and there were significant 
differences in consumption at low unit prices and in estimated consumption if the reinforcer were 
free. Furthermore, at a single unit price, consumption was not equivalent across seven FR/dose 
combinations, and was significantly less when low nicotine doses or high FRs were used. 
These data have important implications of the framework of behavioral economics and a 
nicotine reduction policy. They call into question a fundamental assumption within behavioral 
economics. While the results of the present study are specific to nicotine, they may have broader 
implications for other drugs of abuse or for reinforcers in general. Future researchers should 
investigate the generalizability of these results. These data also suggest that increases in the cost 
of cigarettes may not be thought of as functionally equivalent to decreases in nicotine content, 
and so we cannot use existing information regarding cigarette taxation to make predictions about 
a nicotine reduction policy.  
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